Press release
X-Linked Retinitis Pigmentosa Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
In the X-Linked Retinitis Pigmentosa Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, X-Linked Retinitis Pigmentosa NDA approvals (if any), and product development activities comprising the technology, X-linked Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the X-Linked Retinitis Pigmentosa Pipeline Report
• X-linked Retinitis Pigmentosa Pipeline report offers a comprehensive analysis of 5+ companies and 5+ therapies.
• The leading X-linked Retinitis Pigmentosa Companies includes Biogen, 4 D Molecular therapeutics, Applied Genetics Technology Corporation, and others.
• Promising X-linked Retinitis Pigmentosa Pipeline Therapies includes AAV2/5-RPGR, docosahexaenoic acid OR corn/soy oil placebo, and others.
• The X-linked Retinitis Pigmentosa companies and academics are working to assess challenges and seek opportunities that could influence X-linked Retinitis Pigmentosa R&D. The X-linked Retinitis Pigmentosa pipeline therapies under development are focused on novel approaches to treat/improve X-linked Retinitis Pigmentosa.
Explore more information on the latest breakthroughs in the X-Linked Retinitis Pigmentosa treatment landscape of the report and X-Linked Retinitis Pigmentosa Pipeline Outlook @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
X-Linked Retinitis Pigmentosa Overview
X-linked Retinitis Pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss. Total population affected by X-linked Retinitis Pigmentosa is 1 in 4000 people across the world. Also, as it is a recessive disorder, males are more affected as compared to females, who have two X chromosomes making them carrier for the disorder. Early symptoms for X-linked Retinitis Pigmentosa includes night blindness, and progressive loss of visual field.
X-linked Retinitis Pigmentosa Emerging Drugs Profile
• BIIB 112 (NSR-RPGR): Biogen
Biogen's lead drug candidate, BIIB 112 (NSR-RPGR), is a class of gene therapy molecule which consists of standard AAV8 vector carrying a codon-optimized RPGR gene. The drug is in Phase II/III stage for the treatment of rare X-linked Retinitis Pigmentosa and has been designated orphan drug status. The trial is carried out to evaluate the tolerability as well as the stability of the drug in improving central vision.
• 4D-125: 4 D Molecular Therapeutics
4D Molecular Therapeutics "lead" drug 4D-125 is currently being evaluated for the safety and maximum tolerance dose for the treatment of X-linked Retinitis Pigmentosa. 4D-125 is an AAV gene therapy with an optimized vector designed to deliver a functional RPGR gene copy to the photoreceptors in retina.
Request a sample and discover the recent advances in X-Linked Retinitis Pigmentosa Pipeline Therapies, visit X-Linked Retinitis Pigmentosa Treatment Landscape @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
X-Linked Retinitis Pigmentosa Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for X-linked Retinitis Pigmentosa. The companies which have their X-linked Retinitis Pigmentosa drug candidates in the mid to advanced stage, Phase II/III include, Biogen and others.
X-Linked Retinitis Pigmentosa Pipeline Segmentation
Phases
• Late-stage products (Phase II/III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
X-linked Retinitis Pigmentosa Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type
X-linked Retinitis Pigmentosa Molecule Types
• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type
Get to know more information about the X-linked Retinitis Pigmentosa Emerging Drugs and Companies of the report @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the X-linked Retinitis Pigmentosa Pipeline Report
• Coverage- Global
• X-linked Retinitis Pigmentosa Companies- Biogen, 4 D Molecular therapeutics, Applied Genetics Technology Corporation, and others.
• X-linked Retinitis Pigmentosa Pipeline Therapies- AAV2/5-RPGR, docosahexaenoic acid OR corn/soy oil placebo, and others.
• X-linked Retinitis Pigmentosa Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
To know more facts about the X-linked Retinitis Pigmentosa Pipeline Insights Report, View Here- X-linked Retinitis Pigmentosa Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. X-linked Retinitis Pigmentosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. X-linked Retinitis Pigmentosa - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. X-linked Retinitis Pigmentosa Collaboration Deals
9. Late Stage Products (Phase II/III)
10. BIIB 112 (NSR-RPGR): Biogen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase I/II)
13. 4D-125: 4 D Molecular Therapeutics
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. X-linked Retinitis Pigmentosa Key Companies
19. X-linked Retinitis Pigmentosa Key Products
20. X-linked Retinitis Pigmentosa- Unmet Needs
21. X-linked Retinitis Pigmentosa- Market Drivers and Barriers
22. X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion
23. X-linked Retinitis Pigmentosa Analyst Views
24. X-linked Retinitis Pigmentosa Key Companies
25. Appendix
For further information, refer to the detailed X-Linked Retinitis Pigmentosa Pipeline report, visit X-Linked Retinitis Pigmentosa Emerging Drugs & Companies @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Trending Market Research Reports 2032 | DelveInsight
Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services
Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market
Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market
B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market
UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Shingles Market- https://www.delveinsight.com/report-store/shingles-market
Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market
Tay-Sachs Disease Market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Shigellosis Market- https://www.delveinsight.com/report-store/shigellosis-market
Gene Therapy In CNS Disorder Market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
Hypertrophic Cardiomyopathy Market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
Varicella Zoster (HHV-3) Infections Market- https://www.delveinsight.com/report-store/varicella-zoster-hhv-3-infections-market
Vasculitis Market- https://www.delveinsight.com/report-store/vasculitis-market
Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release X-Linked Retinitis Pigmentosa Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 2900965 • Views: …
More Releases from DelveInsight Business Research
Stuttering Market Positioned for Accelerated Development Through 2034, DelveInsi …
The Stuttering market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stuttering pipeline products will significantly revolutionize the Stuttering market dynamics.
DelveInsight's "Stuttering Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stuttering, historical and forecasted epidemiology as well as the Stuttering market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Acute Ischemic Stroke Pipeline 2025: Therapies, MOA Insights, and Key Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Ischemic Stroke pipeline constitutes 20+ key companies continuously working towards developing 25+ Acute Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Insomnia Market to Expand Significantly by 2034, States DelveInsight Report
The Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Insomnia pipeline products will significantly revolutionize the Insomnia market dynamics.
DelveInsight's "Insomnia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Insomnia, historical and forecasted epidemiology as well as the Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the…
Global Clinical Trial Support Services Market to reach USD 43,160.56 million by …
According to DelveInsight's analysis, The clinical trial support services market is witnessing significant growth, driven by the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders. This rise has resulted in a surge in clinical trial activities, higher R&D investments, and greater focus on drug development. Moreover, expanding collaborations between pharmaceutical, biotechnology, and medical device companies are boosting the need for specialized services, including regulatory assistance, data…
More Releases for Retinitis
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic…
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic…
Retinitis Pigmentosa Market Growth and Treatment Advancements
The retinitis pigmentosa (RP) market has garnered considerable attention in recent years due to its profound impact on individuals' lives. As one of the leading causes of hereditary blindness, RP is a genetic eye disorder that progressively leads to vision loss. The market for retinitis pigmentosa treatments was valued at USD 14.02 billion in 2023, and with significant advancements on the horizon, it is expected to reach USD 21.40 billion…
Retinitis Pigmentosa Market Research and Market Share Insights
The Business Research Company recently released a comprehensive report on the Global Retinitis Pigmentosa Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Retinitis Pigmentosa (Retinitis) Market Analysis and Future Prospects for 2030
The world of the retinitis pigmentosa (retinitis) market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing…
